Condition: Differentiated Thyroid Cancer · Sponsor: Istituti Clinici Scientifici Maugeri SpA
This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.
This description comes directly from the study's public registry record.
Serena Barbaro, M.Sc. · +39 (0)3982592326 · CTCstaff.pavia@icsmaugeri.it
Always discuss trial participation with your own doctor first.
| Istituti Clinici Scientifici Maugeri | Pavia, Lombardy, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05852223